Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Adlai Nortye of Hangzhou Closes $50 Million B Round

publication date: Jun 26, 2018

Adlai Nortye, a Hangzhou biopharma, closed a $50 million Series B round led by Yuanming Capital. Adlai Nortye describes itself as a science-led discovery and in-licensing biopharma focused on new drugs for cancer and metabolic diseases. So far, it has three announced molecules of its own, currently in pre-clinical development, and it has in-licensed rights to two clinical-stage immunoncology products -- one from Canada's Oncolytics Biotech and the other from Eisai of Japan. More details....

Stock Symbols: (TSX: ONC) (TYO: 4523)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital